PROCEPT BioRobotics Corp
For the period ended Dec 31, 2024. Filed Feb 27, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 27, 2025
PRCT$22.37+8.5%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Financial Statements: Consolidated Balance Sheets F-
(in thousands, except per share data)
| December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $333,725 | $257,222 |
| Accounts receivable, net, | 83,496 | 48,376 |
| Inventory | 56,168 | 39,756 |
| Prepaid expenses and other current assets | 8,453 | 5,213 |
| Total current assets | 481,842 | 350,567 |
| Restricted cash, non-current | 3,038 | 3,038 |
| Property and equipment, net | 26,709 | 28,748 |
| Operating lease right-of-use assets, net | 18,941 | 20,241 |
| Intangible assets, net | 932 | 1,204 |
| Other assets | 2,555 | 919 |
| Total assets | $534,017 | $404,717 |
| Liabilities and Stockholders' Equity | ||
| Current liabilities: | ||
| Accounts payable | $10,032 | $13,499 |
| Accrued compensation | 21,537 | 16,885 |
| Deferred revenue | 9,565 | 5,656 |
| Operating leases, current | 1,910 | 1,683 |
| Loan facility derivative liability | 2,000 | 1,886 |
| Other current liabilities | 8,089 | 6,318 |
| Total current liabilities | 53,133 | 45,927 |
| Long-term debt | 51,472 | 51,339 |
| Operating leases, non-current | 26,868 | 26,182 |
| Other non-current liabilities | 324 | 517 |
| Total liabilities | 131,797 | 123,965 |
| Commitments and contingencies (Note 12) | ||
| Stockholders’ equity: | ||
| Preferred stock, $0.00001 par value; | ||
| Authorized shares: 10,000 at December 31, 2024 and 2023, respectively | ||
| Issued and outstanding shares: none at December 31, 2024 and 2023 | — | — |
| Common stock, $0.00001 par value; | ||
| Authorized shares: 300,000 at December 31, 2024 and 2023, respectively | ||
| Issued and outstanding shares: 54,718 and 50,771 at December 31, 2024 and 2023 | — | — |
| Additional paid-in capital | 948,091 | 735,240 |
| Accumulated other comprehensive gain | 114 | 84 |
| Accumulated deficit | (545,985) | (454,572) |
| Total stockholders’ equity | 402,220 | 280,752 |
| Total liabilities and stockholders’ equity | $534,017 | $404,717 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.